NA
SXTP icon

NewEdge Advisors’s 60 Degrees Pharmaceuticals SXTP Stock Holding History

NewEdge Advisors’s Portfolio SXTP Stock Details SXTP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$88 Buy
+50
New +$142 ﹤0.01% 4088

Other funds holding SXTP

KCM
Kathmere Capital Management Wayne, Pennsylvania $1.62B AUM 17.7% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
TPWA
Twin Peaks Wealth Advisors Burlingame, California $397M AUM 23.23% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

NewEdge Advisors's SXTP Position: Q1 2026 in Review

NewEdge Advisors opened a new position in 60 Degrees Pharmaceuticals (SXTP) in Q1 2026: 50 shares worth $88. The stake represents ﹤0.01% of the portfolio and ranks #4088 among its holdings.

8 funds tracked by Wall St. Rank hold SXTP as of Q1 2026.

  • NewEdge Advisors held 50 shares of 60 Degrees Pharmaceuticals worth $88 as of Q1 2026.
  • 60 Degrees Pharmaceuticals was a new NewEdge Advisors position in Q1 2026.
  • 60 Degrees Pharmaceuticals made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #4088 holding.
  • 8 funds tracked by Wall St. Rank held 60 Degrees Pharmaceuticals as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.